Zobrazeno 1 - 10
of 144
pro vyhledávání: '"EGFR Activating Mutation"'
Autor:
Qiaoyou Weng, Junguo Hui, Hailin Wang, Chuanqiang Lan, Jiansheng Huang, Chun Zhao, Liyun Zheng, Shiji Fang, Minjiang Chen, Chenying Lu, Yuyan Bao, Peipei Pang, Min Xu, Weibo Mao, Zufei Wang, Jianfei Tu, Yuan Huang, Jiansong Ji
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
ObjectivesTo develop and validate a radiomic feature-based nomogram for preoperative discriminating the epidermal growth factor receptor (EGFR) activating mutation from wild-type EGFR in non-small cell lung cancer (NSCLC) patients.MaterialA group of
Externí odkaz:
https://doaj.org/article/68f67f8d997a4dfaa52daad12d5b3858
Autor:
Yong Xu, Hui Yang, Hao Wei, Youling Gong, Jiang Zhu, Yongmei Liu, Feng Peng, Meijuan Huang, Jianxin Xue, Yan Zhang, Bingwen Zou, Jin Wang, You Lu, Lin Zhou, Xiaojuan Zhou
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:2589-2598
This study aimed to explore the clinical value of SBRT for primary lung lesions of EGFR-mutant NSCLC patients with non-oligometastatic disease during first-line EGFR-TKI treatment. We identified patients with stage IV EGFR-mutant non-oligometastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f30b57030b35d1dc56e31e5eddfa402
https://doi.org/10.1007/s00432-021-03831-z
https://doi.org/10.1007/s00432-021-03831-z
Autor:
Weibo Mao, Chenying Lu, Chuanqiang Lan, Liyun Zheng, Yuan Huang, Shiji Fang, Jianfei Tu, Wang Hailin, Zufei Wang, Jiansheng Huang, Minjiang Chen, Yuyan Bao, Jiansong Ji, Min Xu, Junguo Hui, Qiaoyou Weng, Chun Zhao, Peipei Pang
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
ObjectivesTo develop and validate a radiomic feature-based nomogram for preoperative discriminating the epidermal growth factor receptor (EGFR) activating mutation from wild-type EGFR in non-small cell lung cancer (NSCLC) patients.MaterialA group of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33a4371a43a0c4119418589da0500298
https://doi.org/10.3389/fonc.2021.590937
https://doi.org/10.3389/fonc.2021.590937
Autor:
Mario Miccoli, Iacopo Petrini, Marzia Del Re, Antonio Chella, Marina Chiara Garassino, Giulia Gianfilippo, Daniele Pozzessere, Francesca Mazzoni, Stefania Crucitta, Giuliana Restante, Eleonora Rofi, Romano Danesi, Simona Valleggi
Publikováno v:
Clinical Lung Cancer. 21:232-237
Background Insights into the mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) could provide important information for further patient management, including the choice of second-line treatment. The E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fc0c64fcf247860c3459edc51caab4c
https://doi.org/10.1016/j.cllc.2019.10.003
https://doi.org/10.1016/j.cllc.2019.10.003
Autor:
Maria Nirvana Formiga, Cláudia A.A. de Paula, Malu Viter da Rosa Barbosa, Giovana Tardin Torrezan, Dirce Maria Carraro, Vladmir Cláudio Cordeiro de Lima
Publikováno v:
Clinical Lung Cancer. 21:e37-e44
Background Lung cancer represents around 3.6% of all Li-Fraumeni Syndrome (LFS)-associated tumors. A high prevalence of p.R337H germline mutation in the TP53 gene has been observed in Brazil and family histories of cancer associated with this variant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7f35e952c552820dd53e4ff945e789a
https://doi.org/10.1016/j.cllc.2019.11.012
https://doi.org/10.1016/j.cllc.2019.11.012
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Zhengquan Yu, Xuejuan Gao, Jianwei Shuai, Wei Yin, Liyu Liu, Xiao Zhou, Ruchuan Liu, Yanfeng Zhao, Yi Bao
Publikováno v:
Cancer Management and Research. 11:9621-9630
Purpose Previous studies have shown that the presence of EGFR T790M mutation may reduce the treatment efficacy of tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancer. However, little is known about the clinical features and outcomes of EGFR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b435b4f1e8c9301e1b9844c33eceb98
https://doi.org/10.2147/cmar.s216721
https://doi.org/10.2147/cmar.s216721
Autor:
Wang Jing, Ning An, Li Kong, Hui Zhu, Haoyi Wang, Wenxiao Jia, Xiaoyang Zhai, Ji Li, Jinming Yu
Publikováno v:
OncoTargets and therapy
Ning An,1 Haoyi Wang,2 Ji Li,3 Xiaoyang Zhai,3 Wang Jing,3 Wenxiao Jia,3 Li Kong,3 Hui Zhu,3 Jinming Yu3 1Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, People’s Republic of China; 2Department
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7505e532e087111aee8848c2fe4db7c
http://europepmc.org/articles/PMC6790348
http://europepmc.org/articles/PMC6790348
Autor:
Sung-Liang Yu, Shr-Uen Lin, Chong-Jen Yu, Chia-Ching Chang, Chao-Chi Ho, Huei-Wen Chen, Chih-An Lin, Pan-Chyr Yang, Hsuan-Yu Chen
Publikováno v:
Journal of Thoracic Oncology. 14:513-526
Introduction Approximately 5% of patients with EGFR-activating mutations acquire EGFR tyrosine kinase inhibitor (TKI) resistance through SCLC transformation. However, the reason for the poor outcome and the molecular basis of EGFR-mutant SCLC that ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd266093c7a15db9b5344e4d61a35b59
https://doi.org/10.1016/j.jtho.2018.11.021
https://doi.org/10.1016/j.jtho.2018.11.021
Autor:
Fumio Imamura, Kazumi Nishino, Toru Kumagai, Shinji Atagi, Hidekazu Suzuki, Tomonori Hirashima, Norio Okamoto, Yoshihiko Taniguchi, Akihiro Tamiya, Motohiro Tamiya
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
The most frequent mechanism of resistance after 1st/2nd-generation (G) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) is secondary point mutation Thr790Met (T790M) in EGFR. Afatinib followed by osimertinib (Afa group) may p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::792ae69f793f11937cf38621bd9686c5
http://europepmc.org/articles/PMC8099906
http://europepmc.org/articles/PMC8099906